Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature DOI Creative Commons
Gaetano Licata, Mariachiara Arisi,

Caterina Mariarosaria Giorgio

и другие.

Dermatology and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Май 15, 2025

Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis characterized by hyperkeratotic nodules and persistent itch-scratch cycle. Recent insights highlight the role of T helper type 2 cell (Th2)-driven immune dysregulation neuroinflammation, with cytokines such as interleukin (IL)-4, IL-13, IL-31 implicated in disease pathogenesis. PN associated significant morbidity multiple comorbidities, conventional therapies often yield suboptimal outcomes, underscoring need for targeted treatments. A systematic review was conducted using PubMed, Scopus, Google Scholar to identify studies published from January 2020 March 2025 on pathogenesis treatment. Search terms included combinations "prurigo nodularis," "biologic therapy," "JAK inhibitors," "IL-4," "IL-13," "targeted therapy." Of 123 articles screened, 26 were selected basis inclusion criteria prioritizing biologics, JAK inhibitors, randomized controlled trials, cohort studies, real-world evidence. Advances understanding neuroimmune have led development novel therapies. Dupilumab, targeting IL-4Rα, demonstrated reductions pruritus lesion burden phase III trials (PRIME/PRIME2) approved US Food Drug Administration (FDA) European Medicines Agency (EMA). Nemolizumab, an IL-31RA antagonist, received EMA approval shows rapid sustained efficacy. Other promising agents include vixarelimab (dual IL-31/oncostatin M (OSM) blockade), rocatinlimab (anti-OX40), anti-IgE therapy omalizumab. Biomarker-driven endotyping (e.g., eosinophilia, race-specific cytokine profiles) may refine patient selection. Biologics inhibitors represent paradigm shift management, offering durable relief through neurogenic modulation. Dupilumab nemolizumab emerge first-line favorable safety profiles, while provide refractory cases. The heterogeneity underscores importance personalized treatment approaches based immunologic profiling. Targeted are revolutionizing Integrating clinical efficacy, endotyping, data will be pivotal optimizing therapeutic strategies, enhancing personalizing care prurigo nodularis.

Язык: Английский

Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature DOI Creative Commons
Gaetano Licata, Mariachiara Arisi,

Caterina Mariarosaria Giorgio

и другие.

Dermatology and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Май 15, 2025

Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis characterized by hyperkeratotic nodules and persistent itch-scratch cycle. Recent insights highlight the role of T helper type 2 cell (Th2)-driven immune dysregulation neuroinflammation, with cytokines such as interleukin (IL)-4, IL-13, IL-31 implicated in disease pathogenesis. PN associated significant morbidity multiple comorbidities, conventional therapies often yield suboptimal outcomes, underscoring need for targeted treatments. A systematic review was conducted using PubMed, Scopus, Google Scholar to identify studies published from January 2020 March 2025 on pathogenesis treatment. Search terms included combinations "prurigo nodularis," "biologic therapy," "JAK inhibitors," "IL-4," "IL-13," "targeted therapy." Of 123 articles screened, 26 were selected basis inclusion criteria prioritizing biologics, JAK inhibitors, randomized controlled trials, cohort studies, real-world evidence. Advances understanding neuroimmune have led development novel therapies. Dupilumab, targeting IL-4Rα, demonstrated reductions pruritus lesion burden phase III trials (PRIME/PRIME2) approved US Food Drug Administration (FDA) European Medicines Agency (EMA). Nemolizumab, an IL-31RA antagonist, received EMA approval shows rapid sustained efficacy. Other promising agents include vixarelimab (dual IL-31/oncostatin M (OSM) blockade), rocatinlimab (anti-OX40), anti-IgE therapy omalizumab. Biomarker-driven endotyping (e.g., eosinophilia, race-specific cytokine profiles) may refine patient selection. Biologics inhibitors represent paradigm shift management, offering durable relief through neurogenic modulation. Dupilumab nemolizumab emerge first-line favorable safety profiles, while provide refractory cases. The heterogeneity underscores importance personalized treatment approaches based immunologic profiling. Targeted are revolutionizing Integrating clinical efficacy, endotyping, data will be pivotal optimizing therapeutic strategies, enhancing personalizing care prurigo nodularis.

Язык: Английский

Процитировано

0